Conference Reports for NATAP

The International Liver Congress™ EASL - European Association for the Study of the Liver 2019 April 10-14 Vienna Austria Back

PRO: Testing for HCV Resistance-Associated Variants (RAVs) in Patients After DAA Failure and Impact on Subsequent Drug Selection       EASL 2019 Vienna Ira M. Jacobson, M.D. Professor of Medicine Director of Hepatology NYU Langone Health   pdf of slide talk attached   this session had 3 talks, this PRO testing & then Jean Michel Pawlotsky the CON and a summary review afterwards by Christoph Sarrazin. Jules   WEBCAST: https://easl.meta-dcr.com/ilc2019/crs/pro-testing-for-hcv-resistance-associated-variants-ravs-in-patients-after-daa-failure-and-impact-on-subsequent-drug-selection AASLD-SF 2018: High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens